NCT05403684

Brief Summary

The primary hypothesis is that very preterm infants between 28 0/7 to 31 6/7 weeks with a birth weight from 1000-1999 grams allocated to the HV breastmilk group (200-240 mL/kg/day) until hospital discharge or 40 weeks' post-menstrual age (PMA), whichever comes first, will have increased growth velocity compared to those given UV breastmilk (140-180 mL/kg/day).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
214

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 3, 2022

Completed
10 days until next milestone

Study Start

First participant enrolled

June 13, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 28, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 10, 2023

Completed
Last Updated

February 14, 2023

Status Verified

February 1, 2023

Enrollment Period

7 months

First QC Date

May 23, 2022

Last Update Submit

February 11, 2023

Conditions

Keywords

breastmilkhindmilkhigh-volume breastfeedingpostnatal growth restrictionpreterm

Outcome Measures

Primary Outcomes (1)

  • Weight gain

    Average change in weight between enrolment (baseline) up to 40 weeks post-menstrual age (PMA) or hospital discharge, whichever comes first.

    Baseline up to 40 weeks PMA.

Secondary Outcomes (6)

  • Head circumference

    Baseline up to 40 weeks PMA.

  • Mid-arm circumference

    Baseline up to 40 weeks PMA.

  • Length

    Baseline up to 40 weeks PMA.

  • Length of hospital stay

    Baseline up to 40 weeks PMA.

  • Characterise acceptability, feasibility, and feeding tolerance by breastfeeding women and their infants

    Through study completion, on average 8 weeks after enrolment

  • +1 more secondary outcomes

Other Outcomes (3)

  • Neonatal mortality

    28 days after birth

  • Weight at 40 weeks PMA

    40 weeks PMA

  • Postpartum Depression

    6-8 weeks postnatal

Study Arms (2)

Usual-volume breastfeeding (UV Group)

NO INTERVENTION

Infants will receive cup-feeding (to standardize the volume at each feeding) per standard of care guidelines (SOC: 140-180 mL/kg/day) with volumes adjusted for weight and infant age.

High-volume breastfeeding (HV Group)

EXPERIMENTAL

Along with SOC volume provided via cup-feeding, the mother will continue to express and feed the baby hind-milk reaching 240 mL/kg/day with volumes adjusted for weight and infant age (200-240 ml/kg/day).

Other: High-volume breastmilk

Interventions

Preterm infants will be given high-volume breastmilk

High-volume breastfeeding (HV Group)

Eligibility Criteria

Age1 Day - 7 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Between 28 0/7 to 31 6/7 weeks of age or weighing between 1000-1999 grams,
  • Admitted to the UTH NICU within 24 hours after birth, and
  • Infants who have reached feeding volume ≥120 mL/kg/day at time of randomization

You may not qualify if:

  • Who are deemed unstable by the neonatologist,
  • With necrotizing enterocolitis or intestinal perforation
  • Known gastrointestinal malformations,
  • Major malformations or congenital anomalies, and
  • Whose parents do not provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Teaching Hospital

Lusaka, 10101, Zambia

Location

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Waldemar Carlo, MD

    University of Alabama at Birmingham

    STUDY CHAIR
  • Colm Travers, MD

    University of Alabama at Birmingham

    STUDY DIRECTOR
  • Albert Manasyan, MD, MPH

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: The proposed study is a non-blinded randomized controlled trial with a 1:1 parallel allocation of infants to higher-volume feedings (200-240 ml/kg/day) or usual-volume feedings (140-180 ml/kg/day) using computer-generated random-block sequences.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 23, 2022

First Posted

June 3, 2022

Study Start

June 13, 2022

Primary Completion

December 28, 2022

Study Completion

February 10, 2023

Last Updated

February 14, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will share

Study data will be shared upon a reasonable request to the study PI.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data will be available for sharing following publication of study findings (or during submission for publication if requested by the journal)
Access Criteria
Following a reasonable request to the study PI.

Locations